Biogen (BIIB) concentration risks

The company's disclosed concentration profile is limited to two product-level revenue dependencies, both of which carry a small-share disclosed size — meaning neither individually constitutes a dominant portion of total revenue, but each clears the threshold of materiality that requires specific disclosure. Product sales for TYSABRI and SPINRAZA each accounted for more than 10.0% of total revenue for the years ended December 31, 2025, placing both in the named-disclosure tier as individually significant contributors to the top line. The character of both exposures is structural rather than dependency-driven — they reflect the company's established product base in neuroscience, where revenues from these franchises arise from prescribing patterns, formulary positions, and disease prevalence rather than from contractual reliance on a single customer or counterparty that could be withdrawn at short notice. TYSABRI and SPINRAZA are therefore best understood as franchise concentration risks: each is sensitive to competitive entry, label changes, or payer coverage decisions specific to that drug rather than to the behavior of any single buyer. What the profile does not disclose is a third category that could compound these exposures — no customer, geographic, or supplier concentration is quantified in the source claims. The two product disclosures, taken together, suggest a revenue base that has achieved some diversification across drug assets while still carrying meaningful individual product exposure. For an investor, the key monitoring variables are the competitive and reimbursement dynamics specific to each franchise rather than macro or counterparty factors.

For the engine’s reasoning on BIIB’s current verdict — including which dimensions drove the score — see the per-dimension breakdown.

Concentration counts reflect items disclosed in each peer’s most recent 10-K; disclosed-size classification uses TrendMatrix’s internal 10-K extraction taxonomy.